drug_type
RELEVANT_DRUG
intervention_type
Biological (autologous CAR T-cell therapy)
drug_description
Autologous anti-CD19 CAR T-cell therapy; patient T cells engineered to express a CD19-directed CAR (with CD3ΞΆ and costimulatory signaling) to proliferate and kill CD19+ malignant B cells.
nci_thesaurus_concept_id
C155878
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
relmacabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor containing CD3zeta and costimulatory signaling domains. Binding to CD19 on malignant B cells activates T-cell effector functions, driving proliferation, cytokine release, and cytolytic killing of CD19-positive cells.
drug_name
Relmacabtagene Autoleucel
nct_id_drug_ref
NCT06093841